Table 1.
Associations between TDLU measures and END tertiles among women with benign breast disease, overall and by biopsy diagnosis subtypes, The BREAST Stamp Project (N=224 women; 262 biopsy targets).
| END |
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TDLU measures | Overall, n=262 |
TDLU measures | Benign Non-Proliferative disease, n=90 |
TDLU measures | Benign Proliferative disease, n=172 |
||||||||||||
| T1 | T2 | T3 | Unadjusted | Adjusted for age and BMI | T1 | T2 | T3 | Unadjusted | Adjusted for age and BMI | T1 | T2 | T3 | Unadjusted | Adjusted for age and BMI | |||
| N=89 | N=87 | N=86 | OR (95% CI)† | OR (95% CI)† | N=31 | N=29 | N=30 | OR (95% CI)† | OR (95% CI)† | N=59 | N=56 | N=57 | OR (95% CI)† | OR (95% CI)† | |||
| TDLU count/100 mm2 | TDLU count/100 mm2 | TDLU count/100 mm2 | |||||||||||||||
| T1 (0 – 6.05) | 40 | 29 | 20 | Ref | T1 (0 – 2.0) | 13 | 9 | 9 | Ref | Ref | T1 (0 – 9.5) | 26 | 19 | 14 | Ref | Ref | |
| T2 (6.06 – 24.8) | 30 | 36 | 21 | 1.35 (0.79, 2.30) | 1.32 (0.77, 2.27) | T2 (2.1 – 14.5) | 11 | 12 | 6 | 0.94 (0.39, 2.23) | 1.04 (0.42, 2.60) | T2 (9.6 – 31.3) | 23 | 19 | 14 | 1.11 (0.56, 2.20) | 1.01 (0.50, 2.02) |
| T3 (24.9 – 200) | 19 | 22 | 45 | 3.55 (2.97, 6.40) | 3.42 (1.87, 6.28) | T3 (14.6 – 200) | 7 | 8 | 15 | 2.55 (0.98, 6.62) | 3.11 (1.15, 8.42) | T3 (31.4 – 173) | 10 | 18 | 29 | 3.49 (1.73, 7.06) | 3.07 (1.46, 6.45) |
| P-trend | <0.0001 | 0.0002 | P-trend | 0.07 | 0.03 | P-trend | 0.0007 | 0.0045 | |||||||||
| P-valuea | <0.0001 | P-valuea | 0.14 | P-valuea | 0.004 | ||||||||||||
| Weighted kappa | 0.23 (0.13, 0.33) | Weighted kappa | 0.18 (0.01, 0.35) | Weighted kappa | 0.21 (0.09, 0.32) | ||||||||||||
| Median TDLU span, μ | Median TDLU span, μ | Median TDLU span, μ | |||||||||||||||
| T1 (115 – 221.0) | 28 | 27 | 19 | Ref | Ref | T1 (115 – 204.0) | 10 | 6 | 6 | Ref | Ref | T1 (125 – 227.0) | 21 | 21 | 11 | Ref | Ref |
| T2 (221.1 – 284.5) | 26 | 22 | 24 | 1.24 (0.66, 2.30) | 1.18 (0.63, 2.20) | T2 (204.1 – 258.5) | 6 | 9 | 6 | 1.58 (0.50, 5.03) | 1.60 (0.50, 5.15) | T2 (227.1 – 286.0) | 17 | 13 | 21 | 1.83 (0.86, 3.93) | 1.62 (0.75, 3.52) |
| T3 (284.6 – 628) | 16 | 28 | 29 | 1.97 (1.09, 3.57) | 1.64 (0.88, 3.05) | T3 (258.6 – 628) | 3 | 8 | 10 | 3.44 (1.05, 11.27) | 3.41 (1.07, 10.92) | T3 (286.1 – 578) | 14 | 19 | 18 | 1.80 (0.91, 3.57) | 1.34 (0.65, 2.79) |
| P-trend | 0.02 | 0.11 | P-trend | 0.048 | 0.04 | P-trend | 0.08 | 0.41 | |||||||||
| P-valuea | 0.17 | P-valuea | 0.21 | P-valuea | 0.17 | ||||||||||||
| Weighted kappa | 0.09 (−0.01, 0.2)‡ | Weighted kappa | 0.22 (0.03, 0.42)‡ | Weighted kappa | 0.07 (−0.05, 0.19)‡ | ||||||||||||
| No TDLUs observed | 19 | 10 | 14 | No TDLUs observed | 12 | 6 | 8 | No TDLUs observed | 7 | 3 | 7 | ||||||
| Median acini count per TDLU | Median acini count per TDLU | Median acini count per TDLU | |||||||||||||||
| 1 – 10 | 48 | 46 | 33 | Ref | Ref | 1 – 10 | 16 | 12 | 9 | Ref | Ref | 1 – 10 | 32 | 34 | 24 | Ref | Ref |
| >10 – 15 | 10 | 6 | 7 | 0.95 (0.40, 2.28) | 0.91 (0.37, 2.22) | >10 – 15 | 1 | 3 | 4 | 3.91 (0.92, 16.71) | 4.37 (0.95, 20.05) | >10 – 15 | 10 | 1 | 4 | 0.38 (0.11, 1.29) | 0.31 (0.094, 1.04) |
| ≥16 | 12 | 25 | 32 | 2.57 (1.49, 4.42) | 2.40 (1.39, 4.15) | ≥16 | 2 | 8 | 9 | 3.74 (1.32, 10.59) | 3.90 (1.41, 10.80) | ≥16 | 10 | 18 | 22 | 2.12 (1.14, 3.94) | 1.92 (1.02, 3.61) |
| P-trend | 0.001 | 0.003 | P-trend | 0.009 | 0.004 | P-trend | 0.03 | 0.08 | |||||||||
| P-valuea | 0.01 | P-valuea | 0.07 | P-valuea | 0.006 | ||||||||||||
| Weighted kappa | 0.16 (0.06, 0.26)‡ | Weighted kappa | 0.24 (0.07, 0.42)‡ | Weighted kappa | 0.10 (−0.02, 0.22)‡ | ||||||||||||
| No TDLUs observed | 19 | 10 | 14 | No TDLUs observed | 12 | 6 | 8 | No TDLUs observed | 7 | 3 | 7 | ||||||
The cutoffs of END tertiles among overall patients were: T1: 3842 – 9598.0, T2: 9598.1 – 10674.0, T3: 10674.1 – 13757; The cutoffs of END tertiles among patients with non-proliferative breast disease were: T1: 3842 – 9178.0, T2: 9178.1 – 10569.0, T3: 10569.1 – 13461; The cutoffs of END tertiles among patients with proliferative breast disease were: T1: 4069 – 9751.0, T2: 9751.1 – 10749.0, T3: 10749.1 – 13757.
ORs and 95% CI estimates calculated using ordinal multivariate logistic regression models. Multivariable models adjusted for age and BMI as categorized trends. P-trend <0.05 are presented in bold font.
Weighted kappa test excluded biopsy targets with zero TDLU observed. P-value less than 0.05 is in bold font.
P-value is from Chi-square test. P-value less than 0.05 is in bold font.
BMI, body mass index; CI, confidence interval; END, epithelial nuclear density; OR, odds ratio; TDLU, terminal duct lobular unit, T, tertile.